Ceritinib enables stereotactic radiosurgery to a previously untreatable symptomatic brain metastasis in a patient with ALK rearranged non-small cell lung cancer

摘要: Abstract Brain metastases are common in non-small cell lung cancer (NSCLC) and traditionally have been treated with whole brain radiation therapy, surgery, or stereotactic radiosurgery, a limited role for systemic therapy. However, the development of highly active small molecule tyrosine kinase inhibitors patients NSCLC characterized by key driver mutations has generated interest use therapy as an alternative to potentially morbid local metastases. We present case 59 year old Caucasian female anaplastic lymphoma (ALK) rearranged who developed large symptomatic metastasis not initially amenable radiosurgery (SRS) while receiving ALK inhibitor crizotinib. The lesion regressed quickly after initiation ceritinib, next generation known activity against crizotinib refractory NSCLC, thereby allowing SRS standard craniotomy consolidative